Boc-Cys(Et)-OMe | 1020540-80-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Cys(Et)-OMe
• 英文别名: methyl (2R)-3-ethylsulfanyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 1020540-80-0
• 化学式: C₁₁H₂₁NO₄S
• 分子量: 263.358
• InChiKey: GAFALSMJUGFZDQ-QMMMGPOBSA-N

物化性质

• 沸点：
  376.0±37.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Boc-Cys(Et)-OMe 在 2,4,6-三甲基苯磺酰羟胺 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以79%的产率得到2-叔丁氧羰基氨基丙烯酸甲酯
  参考文献：
  名称：

  Facile Conversion of Cysteine and Alkyl Cysteines to Dehydroalanine on Protein Surfaces: Versatile and Switchable Access to Functionalized Proteins

  摘要：

  An efficient and robust oxidative elimination of cysteine to dehydroalanine has been discovered. The reaction is induced by O-mesitylenesulfonylhydroxylamine (MSH) and is compatible with methionine. The key elimination has been executed on protein surfaces and allows ready access to different post-translationally modified proteins through conjugate addition of sulfur nucleophiles to dehydroalanine. Treatment of the resulting thioether with MSH results in regeneration of dehydroalanine, allowing a "functional switch" by subsequent addition of a different thiol.

  DOI：

  10.1021/ja800800p
• 作为产物：
  描述：

  N-[(tert-butoxy)carbonyl]-L-cysteine methyl ester 、 碘乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以65%的产率得到Boc-Cys(Et)-OMe
  参考文献：
  名称：

  Biosynthetic diversification of non-ribosomal peptides through activity-based protein profiling of adenylation domains

  摘要：

  与前体定向生物合成相结合，基于活性的非核糖体肽合成酶蛋白质分析为非核糖体肽的生物合成多样化提供了合理的指导。

  DOI：

  10.1039/d3cc02633g

文献信息

• C7- substituted camptothecin analogs
  申请人：Narkunan Kesavaram

  公开号：US20090099224A1

  公开（公告）日：2009-04-16

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7修饰的紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯稳定性；(viii) 保持药效；以及(ix) 具有较低的分子量（例如，分子量<600）。
• [EN] C7-SUBSTITUTED CAMPTOTHECIN ANALOGS<br/>[FR] ANALOGUES DE CAMPTOTHÉCINE SUBSTITUÉS EN C7
  申请人：BIONUMERIK PHARMACEUTICALS INC

  公开号：WO2009051580A1

  公开（公告）日：2009-04-23

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B- ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7-修饰紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯的稳定性；(viii) 保持药物的效力；以及(ix) 具有较低的分子量（例如，分子量<600）。
• C7-SUBSTITUTED CAMPTOTHECIN ANALOGS
  申请人：BIONUMERIK PHARMACEUTICALS, INC.

  公开号：EP2197879B1

  公开（公告）日：2014-01-22
• CHEMICAL MODIFICATION OF PROTEINS
  申请人：ISIS Innovation Limited

  公开号：EP2254900B1

  公开（公告）日：2012-03-14
• Chemical Modification of Proteins
  申请人：R.P. Scherer Technologies, LLC

  公开号：US20160326212A1

  公开（公告）日：2016-11-10

  The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.